Evidence map›Paper›PMID 34992394›Full record

ArticleInfection and drug resistance2021

New β-Lactam Antibiotics and Ceragenins - A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of

Paulina Paprocka, Bonita Durnaś, Angelika Mańkowska, Karol Skłodowski, Grzegorz Król, Magdalena Zakrzewska, Michał Czarnowski, Patrycja Kot, Kamila Fortunka, Stanisław Góźdź and 2 more

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Antibiofilm approaches as a new paradigm for treating infections.Progress in biomedical engineering (Bristol, England) · 2024
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Pathogens (Basel, Switzerland) · 2022
    Review
  14. Article
  15. Oxidative medicine and cellular longevity · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Paulina PaprockaDepartment of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Bonita DurnaśDepartment of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Angelika MańkowskaDepartment of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Karol SkłodowskiDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland.
Grzegorz KrólDepartment of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Magdalena ZakrzewskaDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland.
Michał CzarnowskiDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland.
Patrycja KotDepartment of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Kamila FortunkaDepartment of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Stanisław GóźdźHoly Cross Oncology Center of Kielce, Kielce, Poland.ORCID 0000-0001-6902-3807
Paul B SavageDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.ORCID 0000-0002-4642-6109
Robert BuckiDepartment of Microbiology and Immunology, Institute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.ORCID 0000-0001-7664-9226
Jan Kochanowski University · PLMedical University of Białystok · PLBrigham Young University · USHoly Cross University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing number of infections caused by antibiotic resistant strains of

methodsIn this study, we measured the MIC/MBC values and estimated the ability of tested molecules to prevent bacterial biofilm formation to explore the effectiveness of β-lactam antibiotics ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and ceragenins CSA-13, CSA-44, and CSA-131 against 150 clinical isolates of

resultsCollected data proved that ceragenins at low concentrations are highly active against clinical strains of

conclusionThis data strongly supports the need for further study directed to develop this group of molecules as new antibiotics to fighting infections caused by antibiotic resistant strains of

Indexed as

antibacterial agentsantibiotic resistant bacteriacerageninnew antibioticsPseudomonas aeruginosa

Identifiers

PMID34992394
PMCPMC8715797
OpenAlexW4200517040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.